 |
市場調查報告書
商品編碼
1935298
P2X7受體拮抗劑市場：按藥物、應用和地區分類P2X7 Receptor Antagonists Market, By Drugs, By Application, By Geography |
||||||
據估計，P2x7 受體拮抗劑市場在 2026 年的價值為 1.352 億美元，預計到 2033 年將達到 4.38 億美元，從 2026 年到 2033 年的複合年成長率為 18.3%。
| 報告內容 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 1.352億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 預測期（2026-2033年）複合年成長率： | 18.30% | 2033 年的預測值： | 4.38億美元 |
P2X7受體拮抗劑仍處於研發階段，需要獲得監管部門核准才能上市。製造商必須向美國食品藥物管理局（FDA）提交新藥臨床實驗申請（IND）。所有藥物都必須經過FDA制定的核准流程。與其他新藥一樣，P2X7受體拮抗劑在提交新藥臨床實驗申請（IND）後也需要進行臨床試驗。然而，由於嚴格的監管核准流程，製藥公司在將這些藥物推向市場時面臨許多挑戰。這些因素被認為是影響全球P2X7受體拮抗劑市場及其成長的因素。
市場動態
由於目前缺乏有效的治療方法， P2X7受體拮抗劑類藥物盈利豐厚。主要企業都在加大對該類藥物研發的投入，專利保護可望幫助市場參與者獲得高額收益。重度憂鬱症、情緒障礙、慢性疼痛和發炎等疾病和症狀十分普遍，且發生率呈上升趨勢。根據英國國家醫療服務體系數位部門（NHS Digital）的數據顯示，2016年抗憂鬱症處方箋增幅最大，顯示憂鬱症的流行趨勢。 P2X7受體拮抗劑一旦上市，可望在核准的疾病或適應症領域中佔據可觀的市場。製藥公司也正在透過開發創新藥物（例如AKP-23494954/RQ-00466479（旭化成/RaQualia Pharma））來推動P2X7受體拮抗劑類藥物的發展。預計這些因素將在預測期內支撐全球P2X7受體拮抗劑市場的成長。
本次調查的主要特點
- 本報告對 P2X7 受體拮抗劑市場進行了詳細分析，以 2025 年為基準年，給出了預測期（2026-2033 年）內的市場規模和復合年成長率（%）。
- 它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、區域前景以及主要企業採取的競爭策略的重要見解。
- 該研究根據以下參數對全球 P2X7 受體拮抗劑市場的主要企業進行了分析：公司概況、財務績效、產品系列、地理擴張、分銷策略、關鍵發展和策略。
- 本報告的研究結果將使負責人和企業經營團隊能夠透過技術升級、市場擴張和行銷策略，為未來的產品發布做出明智的決策。
- 這份全球 P2X7 受體拮抗劑市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過各種用於分析 P2X7 受體拮抗劑市場的策略矩陣輕鬆做出決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章 市場動態、監理及趨勢分析
- 管道分析
- 市場動態
- 促進要素
- 抑制因素
- 市場機遇
- 影響分析
- 重大進展
- PEST分析
- 流行病學
4. 2026-2033年全球P2X7受體拮抗劑市場（依藥物類型分類）
- AKP-23494954/RQ-00466479
- EVT 401
- GSK1482160
- JNJ-55308942
- JNJ-54175446
- 其他（例如 AZ11657312）
5. 2026-2033年全球P2X7受體拮抗劑市場（依應用領域分類）
- 中樞神經系統疾病
- 免疫系統疾病
- 其他
6. 2026-2033年全球P2X7受體拮抗劑市場（依地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第7章 競爭情勢
- 公司簡介
- Asahi Kasei Corporation
- GlaxoSmithKline Plc
- Johnson &Johnson
- AstraZeneca Plc
- Evotec AG
- RaQualia Pharma
第8章各節
- 參考
- 調查方法
P2x7 Receptor Antagonists Market is estimated to be valued at USD 135.2 Mn in 2026 and is expected to reach USD 438 Mn by 2033, growing at a compound annual growth rate (CAGR) of 18.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 135.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 18.30% | 2033 Value Projection: | USD 438 Mn |
P2X7 receptor antagonists are still in the developmental stage and will require regulatory approval for introduction into the market. Manufacturers need to file an Investigational New Drug Application (IND) with the U.S. Food & Drug Application (FDA). Every drug is required to go through the approval process set by the FDA. P2X7 antagonists will be going through all the clinical trials after filing an Investigational New Drug (IND) application as any other new drug. However, the pharmaceutical organizations face several challenges for introducing these medications in the market due to a stringent regulatory approval process. These factors are considered in global P2X7 receptor antagonist market and factors affecting global P2X7 receptor antagonist market growth.
Market Dynamics
P2X7 Receptor Antagonists drug category is highly lucrative, as no drug therapies are available in this category. Leading organizations are investing in research and development of drugs in this category, which is expected to help market players in generating high revenue using patent protection. Disease and conditions such as major depressive disorders, mood disorders, chronic pain, and inflammation are highly prevalent and their incidence is also increasing. According to National Health Service Digital (NHS Digital), U.K., antidepressants medications prescriptions observed the largest increase in 2016, indicating the prevalence of depressive disorders. If launched, P2X7 receptor antagonists will be capable of acquiring a significant amount of market share for the disease or indication for which they have been approved. Drug manufacturers are also advancing the P2X7 antagonist drug category by developing innovative drugs such as AKP-23494954/RQ-00466479 (Asahi Kasei/RaQualia Pharma). These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
Key features of the study
- This report provides in-depth analysis of the P2X7 receptor antagonists market and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global P2X7 receptor antagonists market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
- Key companies covered as a part of this study include, Asahi Kasei Corporation, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, Evotec AG, and RaQualia Pharma
- Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
- The global P2X7 receptor antagonists market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the P2X7 receptor antagonists market
Market Segmentation
- Drugs Insights (Revenue, USD Mn, 2026 - 2033)
- AKP-23494954/RQ-00466479
- EVT 401
- GSK1482160
- JNJ-55308942
- JNJ-54175446
- Others (e.g.- AZ11657312)
- Application Insights (Revenue, USD Mn, 2026 - 2033)
- Central Nervous System Disorders
- Immunological Disorders
- Others
- Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GlaxoSmithKline Plc
- Johnson & Johnson
- AstraZeneca Plc
- RaQualia Pharma
- Evotec AG
- Asahi Kasei Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Pipeline Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Epidemiology
4. Global P2X7 Receptor Antagonists Market, By Drugs, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- AKP-23494954/RQ-00466479
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- EVT 401
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- GSK1482160
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- JNJ-55308942
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- JNJ-54175446
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others (e.g.- AZ11657312)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global P2X7 Receptor Antagonists Market, By Application, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Central Nervous System Disorders
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Immunological Disorders
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global P2X7 Receptor Antagonists Market, By Region, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Drugs, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Company Profiles
- Asahi Kasei Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evotec AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- RaQualia Pharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Asahi Kasei Corporation
8. Section
- References
- Research Methodology
- About us and Sales Contact
